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Abstract
Background: Bacterial drug resistance is one of the most significant challenges to human health today. In
particular, effective antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA) are urgently
needed. A causal relationship between nasal commensal S. aureus and infection has been reported. Accordingly,
elimination of nasal S. aureus reduces the risk of infection. Enzymes that degrade bacterial cell walls show promise
as antibacterial agents. Bacteriophage-encoded bacterial cell wall-degrading enzymes exhibit intrinsic bactericidal
activity. P128 is a chimeric protein that combines the lethal activity of the phage tail-associated muralytic enzyme
of Phage K and the staphylococcal cell wall targeting-domain (SH3b) of lysostaphin.
Here we report results of in vitro studies evaluating the susceptibility of staphylococcal strains to this novel protein.
Results: Using the broth microdilution method adapted for lysostaphin, we found that P128 is effective against
S. aureus clinical strains including MRSA, methicillin-sensitive S. aureus (MSSA), and a mupirocin-resistant S. aureus.
Minimum bactericidal concentrations and minimum inhibitory concentrations of P128 (1-64 μg/mL) were similar
across the 32 S. aureus strains tested, demonstrating its bactericidal nature.
In time-kill assays, P128 reduced colony-forming units by 99.99% within 1 h and inhibited growth up to 24 h.
In an assay simulating topical application of P128 to skin or other biological surfaces, P128 hydrogel was efficacious
when layered on cells seeded on solid media. P128 hydrogel was lethal to Staphylococci recovered from nares of
healthy people and treated without any processing or culturing steps, indicating its in situ efficacy. This
methodology used for in vitro assessment of P128 as an agent for eradicating nasal carriage is unique.
Conclusions: The novel chimeric protein P128 is a staphylococcal cell wall-degrading enzyme under development
for clearance of S. aureus nasal colonization and MRSA infection. The protein is active against globally prevalent
antibiotic-resistant clinical isolates and other clinically significant staphylococcal species including S. epidermidis. The
P128 hydrogel formulation was bactericidal against Staphylococci including S. aureus recovered from the nares of
31 healthy people, demonstrating its in situ efficacy.
Background
Antibiotic-resistant Staphylococcus aureus strains emer-
ging from the community as well as hospital environments
represent a global threat [1,2], requiring new approaches
to control this pathogen. The anterior nare is the major
reservoir of S. aureus in humans; 80% of the human popu-
lation may be carriers [3]. A causal relationship between
nasal colonization of S. aureus and serious infection has
been established; thus, eliminating S. aureus nasal carriage
may reduce the risk of infection [4,5]. Coagulase-negative
Staphylococci (CoNS) are known commensal flora of
the skin and mucous membranes and also colonize
human anterior nares. Recently CoNS have been recog-
nised as opportunistic pathogens responsible for the
increasing incidence of serious nosocomial infections,
mainly because of their affinity for the foreign materials
used in prosthetics and indwelling devices. Immunocom-
promised patients, including those undergoing haemodia-
lysis, are especially susceptible to these infections [6,7].
More than 80% of clinical CoNS strains and 30% to 40%
of CoNS obtained from healthy carriers or patients from
the community are resistant to methicillin [8].
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Bactroban Nasal (Mupirocin ointment) has been
approved for nasal clearance of S. aureus and significantly
reduces the risk of postoperative staphylococcal infection
in carriers [9]. However, mupirocin resistance has already
been reported, and its use is restricted in many countries.
A superior product for intranasal prophylaxis in at-risk
patients is therefore an unmet medical need. New chemi-
cal entities take longer to develop, and killing by broad-
spectrum antibiotics is undesirable. Current efforts are
therefore focused on pathogen-specific biological entities
such as peptidoglycan hydrolases [10], antibodies [11], and
other antimicrobial peptides and proteins [12]. For exam-
ple, lysostaphin is a bacterial peptidoglycan hydrolase that
has been extensively studied for its antistaphylococcal
activity in various animal models [13-15]. Bacteriophages
are viruses that infect and kill bacteria and have co-
evolved with bacterial defenses [16]. Bacteriophages have
been used for human therapy in several Eastern European
countries for decades [17]. Although they have not been
used in clinical applications in Western countries, the Uni-
ted States Food and Drug Administration recently
approved the use of bacteriophages to prevent bacterial
contamination in meat [18]. In addition, bacteriophages
are a good source of cell wall-degrading enzymes, which
have been evaluated as antibacterial agents [19-21].
P128 is a novel chimeric protein that derives its staphy-
lococcal cell wall-degrading enzymatic domain from the
gene product, ORF56, of bacteriophage K and the cell
wall-targeting domain (SH3b) from Lysostaphin (Pubmed
accession no. of Lysostaphin gene: M 15686.1). We have
previously reported the construction of this novel chi-
meric protein and assignment of its peptidoglycan hydro-
lase activity to the Cysteine, Histidine-dependent
AmidoHydrolase/peptidase (CHAP) domain. We also
demonstrated the efficacy of P128 in nasal clearance of
methicillin-resistant S. aureus (MRSA; strain USA300) in
a rodent model [22]. P128 is under development for topi-
cal indications including use against S. aureus nasal car-
riage. In this study we tested the antistaphylococcal
activity of P128 by determining minimum inhibitory con-
centration (MIC), minimum bactericidal concentration
(MBC), time-kill kinetics, and activity against Staphylo-
cocci from human nares.
Methods
Bacterial strains
All S. aureus strains used in the study are listed in Table 1.
These include 30 clinical strains (27 MRSA strains and 3
MSSA strains) from the Public Health Research Institute,
New Jersey and two USA 500 strains.
P128 expression and purification
P128 protein was cloned and expressed under the indu-
cible T7 expression system in E. coli ER2566 strain.
Details of cloning and design of the P128 clone-con-
struct were reported previously (22).
To generate a purified preparation of P128 for the stu-
dies reported in this work, expression of P128 protein in
E. coli ER2566 was induced with 1 mM IPTG, at 37°C for
4 h. The induced cell pellet was lysed and the protein in
the supernatant was subjected to 0-50% ammonium sul-
phate precipitation using solid ammonium sulphate at 4°C.
The precipitate was dialysed against 25 mM Tris HCl buf-
fer pH 8.0, passed through an anion exchange column.
Table 1 MIC and MBC of P128 against 32 Staphylococcus
aureus strains
Sl. No. Strain MIC (μg/mL) MBC (μg/mL)
1 BK#13725 2 2
2 BK#9894 2 4
3 BK#2926 (USA100) 2 8
4 BK#13993 4 4
5 BK#14035 4 16
6 BK#12003 4 16
7 BK#13385 4 32
8 BK#15273 4 4
9 BK#14942 4 4
10 BK#19069 (USA300) 4 8
11 BK#11147 4 4
12 BK#15271 4 4
13 BK#14483 4 > 32
14 BK# 13387 4 8
15 BK#13228 8 8
16 BK#14935 8 16
17 BK# 13237 8 32
18 BK#14655 8 8
19 BK#18552 8 16
20 BK#9897 C (USA400) 8 8
21 BK#14284 16 16
22 BK#13180 16 16
23 BK#8374 (COL) 16 64
24 BK#11512 16 16
25 BK#11433 16 16
26 BK#13641 16 64
27 BK#2394 32 64
28 BK#9918 1 1
29 BK#14780 8 8
30 BK#15383 16 16
31 USA500/1 16 ND
32 USA500/2 64 ND
33 S. carnosus, ATCC 51365 0.5 0.5
34 S. aureus, ATCC 25923 4 4
MIC was determined using a modification of the CLSI broth microdilution
method. P128 was tested at 256 to 0.125 μg/mL. S. aureus ATCC 25923 and
S. carnosus ATCC 51365 were used as control strains. MBC was determined
following the CLSI procedure by plating 100 μL from the MIC, MIC × 2, MIC ×
4, and MIC × 8 wells on LB agar, and incubating the plates overnight at 37°C.
Strains 1-30 constitute a global panel of distinct clinical isolates (MRSA,
strains1-27; MSSA, strains 28-30) obtained from the Public Health Research
Institute (NJ, USA); strains 31 and 32 are USA500.
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The unbound fraction (flow through), containing P128
protein, was bound to a cation exchange column using
50 mM sodium acetate buffer at pH 6.0. The bound pro-
tein was eluted using a linear gradient of 0 to 0.5 M
sodium chloride. Fractions containing P128 protein were
extensively dialysed against saline and used for all the
studies.
MIC and MBC
The MIC was determined using a modified Clinical and
Laboratory Standards Institute (CLSI) broth microdilu-
tion procedure [23]. Briefly, microtiter wells were pre-
coated with 0.5% bovine serum albumin (BSA) to prevent
nonspecific P128 adherence to the polystyrene plate,
based on the method published for lysostaphin [24].
Two-fold dilutions of P128 were prepared in Mueller
Hinton broth (MHB; Himedia) supplemented with 0.1%
BSA (Sigma Aldrich), and 50 μL aliquots of the P128
dilutions (0.125-256 μg/mL) were added to the wells.
Bacterial suspensions (0.5 McFarland standard) were
diluted in MHB to achieve 1 × 106 colony-forming units
(CFU) per mL. Then 50 μL aliquots of the cell suspension
were added to wells containing P128. Plates were incu-
bated under static conditions at 35°C for 18 h. The MIC
was defined as the lowest concentration of P128 in which
no visible growth was observed at the end of the incuba-
tion period. The MBC was also determined using the
CLSI procedure. Briefly, 100 μL from the MIC, two times
MIC (MIC × 2), four times MIC (MIC × 4), and eight
times MIC (MIC × 8) wells were plated on Luria Bertani
(LB) agar and incubated at 37°C overnight.
MIC of Vancomycin was determined for a panel of
S. aureus isolates that represented the MIC range of
P128 (1-64 μg/mL) using the CLSI broth microdilution
method. Vancomycin was tested at concentrations of
0.125-256 μg/mL, and MICs were read manually after
24 h of incubation. MBC was also determined using the
CLSI procedure. The reference strain, S. aureus ATCC
25923 was used for quality control of the assay, in case
of both P128 and Vancomycin MIC and MBC
determinations.
Time-kill curve studies
The kinetics of P128 bactericidal activity were assessed in
vitro using six S. aureus strains: BK#13237, BK#9894,
BK#14780, BK#8374, BK#9918, and BK#19069. The cryo-
preserved test strains were plated on LB agar plate and
incubated overnight at 37°C. Several well-isolated colo-
nies were picked up and suspended in MHB broth; the
turbidity was then adjusted to 0.5 McFarland standard
(about 108 CFU/mL). The initial inoculum was prepared
by inoculating 10 μL of each test bacterial suspension
into 20 mL MHB supplemented with 0.1% BSA. After 1 h
in a shaker incubator (37°C, 200 rpm), 2.7 mL aliquots of
the culture were dispensed into four tubes, and 0.3 mL
P128 was added. A 0.3 mL aliquot was immediately
removed to determine the initial CFU (0 h). Incubation
was continued, and 0.3 mL aliquots were taken at 1, 2, 4,
8, and 24 h. The cultures were serially diluted in sterile
saline immediately after sampling and plated on MHB
agar. After overnight incubation of the plates, CFU were
determined. The time-kill curve was plotted based on
bacterial survival at the sampling intervals [25].
Efficacy of P128 hydrogel applied to S. aureus on agar
surface
P128 hydrogel was formulated with hydroxyethyl cellulose
(0.42%), propylene glycol (0.75%), and glycerin (2.25%) as
the main excipients along with P128 protein. A formula-
tion that contained physiological saline in place of P128
(referred to as buffer gel) served as a negative control. LB
agar was poured into 24-well tissue culture plates (Tarson).
S. aureus (BK#13237) cells at 103 CFU/well (Figure 1) and
102 CFU/well (Figure 1) were seeded on LB agar in the
microwells. P128 gel was diluted two-fold in buffer gel to
contain P128 protein at a concentration range of 100 to
1.56 μg/mL. P128 gel preparations were applied to wells
and the plates were incubated at 37°C for 18 h. At the end
of incubation, 20 μL iodonitrotetrazolium chloride (INT
dye; Loba Chemie) prepared in 50 mM sodium phosphate
Figure 1 Efficacy of P128 gel formulation applied to S. aureus
on agar surface. A hydrogel formulation containing P128 protein
(100 to 1.56 μg/mL) was tested for bactericidal activity when
applied topically on S. aureus strain BK#13237 cultured on LB agar:
(a) 103 CFU/well, (b) 102 CFU/well. Well #1 represents the media
control, and well #2 represents the cell control. In both (a) and (b),
P128 gel preparations (100-1.56 μg/mL) were added to wells #3-9;
P128 protein formulated in physiological saline (100 μg/mL) was
added in well #10 as a positive control; buffer gel was added to
well #11 as a negative control. INT dye was added to the visualize
growth of the surviving bacteria.
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buffer, pH 7.0 (30 mg/mL) was added to the wells to visua-
lize viable cells.
Bactericidal activity of P128 in simulated nasal fluid
Activity of P128 was tested in a buffer that simulated the
ionic composition of nasal fluid. The simulated nasal fluid
(SNF) contained 0.87% NaCl, 0.088% CaCl2. 2H20, 0.31%
KCl, and 0.636% BSA [26]. The S. aureus COL strain was
subcultured in LB medium from an overnight culture and
grown at 37°C and 200 rpm until the OD600 reached 1.0
to 1.5 (5 × 108 CFU/mL). 100 μL of this cell suspension
(5 × 107 CFU) was centrifuged at 3000 × g for 10 min and
the cell pellet was suspended in 100 μL of SNF. 100 μL of
P128 prepared in SNF (1.5 μg/mL) was added to the cells.
As a positive control, P128 contained in physiological sal-
ine was added to cells suspended in physiological saline.
After addition of P128, tubes were incubated for 1 h in a
shaker incubator at 37°C, 200 rpm. Cells were then pel-
leted and resuspended in 1 mL LB, and 10-fold dilutions
were plated on LB agar and incubated at 37°C overnight.
Cells treated with SNF or saline served as untreated cell
controls.
Efficacy of P128 gel on nasal Staphylococci in their native
physiological state
Nasal commensal Staphylococci of 31 healthy people were
characterized and evaluated for sensitivity to P128. A dry
swab (Copan Diagnostics) was inserted into each nostril,
rotated six times to cover the entire mucosal surface of
the anterior nare, and slowly withdrawn. The swab from
one nostril of each individual was immersed in a vial con-
taining 200 μL P128 hydrogel (40 μg/200 μL), and a swab
from the other nostril was immersed in a vial containing
200 μL buffer gel (control). The vials were placed in a bio-
safety cabinet for 1 h at ambient temperature (about
25°C). The entire vial contents were then spread on blood
agar plates and incubated overnight at 37°C. CFUs recov-
ered were characterized in terms of colony morphology,
hemolysis on blood agar, Gram stain, and a HiStaph iden-
tification kit (Himedia).
Results and discussion
P128 is a bacteriophage derived staphylococcal cell-wall
degrading enzyme. This protein is under development in
our laboratory for topical therapeutic use in humans. In
this study, we tested the bactericidal activity of P128 pro-
tein on globally prevalent S. aureus clinical strains. We
assessed the biological activity of P128 using various in
vitro assays and under conditions designed to simulate
physiological conditions.
P128 protein preparations used in this study were of >
95% purity. The protein expressed was in the soluble form
in a standard E. coli expression system and purified using
a 2-step ion-exchange chromatography procedure [22].
Susceptibility to P128 determined by MIC and MBC assay
Determination of MIC and MBC is a commonly used
method to assess susceptibility to antimicrobial agents.
We determined the MIC and MBC of P128 for a panel of
31 globally represented strains of S. aureus using modi-
fied CLSI methods [23]. Microtiter plate wells were pre-
coated with BSA before adding P128 to minimize non-
specific adherence and loss of protein to the polypropy-
lene surface. The MIC of P128 for the various strains of
S. aureus ranged from 1 to 64 μg/mL (Table 1). The MIC
at which 50% of the strains tested were inhibited (MIC50)
was 8 μg/mL. The MBC of P128 across S. aureus strains
tested also ranged from 1 to 64 μg/mL; and the MBC50
was found to be 16 μg/mL (Table 1).
MIC and MBC of Vancomycin were determined using
the same procedure that was used in case of P128. For the
reference strain, S. aureus ATCC 25923 MIC and MBC of
Vancomycin was found be 0.5 μg/mL and 2 μg/mL respec-
tively. These values correlate with the reported MIC and
MBC of Vancomycin for this strain, validating the assay
used in this work. Vancomycin was also tested on a panel
of S. aureus strains that represented the MIC range of
P128 (1 to 64 μg/mL). MIC of Vancomycin for these
strains ranged from 0.5 to 1 μg/mL and MBC ranged from
1 to 4 μg/mL (Table 2).
Strains 1-6 were selected from a globally represented
panel of distinct, typed clinical isolates (MSSA, strain 1;
MRSA, strains 2-7) obtained from The Public Health
Research Institute, New Jersey, USA; strain 7 is USA500/2,
and 8 is S. aureus, ATCC 25923
Since MIC relates to growth inhibition activity of an
antimicrobial agent, MBC may be a more appropriate
measure of activity of P128 which is bactericidal in
action.
Table 2 MIC and MBC of Vancomycin against a panel of
S. aureus isolates
Sl. No. Strain Vancomycin
MIC (μg/mL) MBC (μg/mL)
1 BK#9918 0.5 2
2 BK# 2926 1 1
3 BK#19069 1 4
4 BK#9897 1 4
5 BK#8374 1 4
6 BK#2394 1 4
7 USA500/2 1 4
8 S. aureus, ATCC 25923 0.5 2
MIC was determined by modified broth microdilution method following the
CLSI procedure. Vancomycin test concentration was in the range of 256 to
0.125 μg/mL. S. aureus ATCC 25923 was used as the control strain. MBC was
determined following the CLSI procedure by plating 100 μL from the MIC, MIC
× 2, MIC × 4 and MIC × 8 wells on LB agar and incubating the plates at 37°C
overnight. The strains used here span the MIC range of P128.
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Time-kill curve studies
Time-kill assays were performed in accordance with the
CLSI guidelines, with a starting inoculum of 5 × 104
CFU/mL and, various multiples of the MICs. The objec-
tive of this assay was to evaluate concentration-depen-
dent bactericidal activity. In order to find the optimal
concentration required to achieve and maintain >
99.99% killing upto 24 h, sub-MIC levels were not con-
sidered. The detection limit of the time kill curve was
10 CFU/mL.
We determined the number of viable S. aureus cells
remaining at different time intervals after adding P128
protein. Figure 2 shows the time-kill curves of P128 for
six representative strains of S. aureus, which included
five MRSA strains and one MSSA strain. P128 showed
rapid, dose-dependent bactericidal activity against the
MSSA and MRSA strains tested, killing of 99.99% of
cells in all six strains tested within 1 h at the respective
MIC concentration. At the MIC, growth was inhibited
up to 24 h for all five MRSA strains and up to 8 h for
the MSSA strain (BK#9918). However, the cells of
BK#9918 that grew after 8 h were susceptible to P128
(data not shown). Since a concentration 4× the MIC
inhibited growth of this strain for up to 24 h, we sur-
mised that higher concentrations of P128 or repeated
treatments may be required in such cases.
Efficacy of P128 gel formulation applied to S. aureus on
agar surface
The efficacy of P128 hydrogel was tested on solid cul-
ture medium to simulate the conditions of topical nasal
application.
The assay format was designed to check availability of
the protein when applied as a gel formulation. The
objective was also to test efficacy of P128 gel applied to
a surface where low numbers of bacterial cells are pre-
sent. We have used a range of 100-1 μg/mL of protein
concentration in the gel formulation. P128 gel showed
complete clearance at concentrations up to 1.56 μg/mL
(Figure 1).
Bactericidal activity of P128 against S. aureus COL in SNF
Functional efficiency and structural stability of enzymes
can generally be influenced by pH, temperature, and the
composition and concentrations of metal or inorganic
ions in the reaction milieu. Our primary concern was
that monovalent and divalent ions present in nasal fluid
may have a deleterious effect on P128 activity. We there-
fore evaluated the activity of P128 in a composition that
simulated the ionic content of normal human nasal fluid.
We found that P128 reduced the staphylococcal viable
count (CFU) by five orders of magnitude in SNF, com-
parable to the activity observed in case of P128 in physio-
logical saline. Cells incubated in SNF that did not contain
P128 were unaffected (Figure 3). These results indicate
that the protein would not be influenced by the ionic
content of human nasal fluid.
Efficacy of P128 gel on nasal Staphylococci in their native
physiological state
Secreted products and components such as exotoxins,
exoenzymes, surface-associated adhesins, and capsular
polysaccharide play a role modulating host responses to
S. aureus infection [27]. Production of capsular polysac-
charide type 5 by Staphylococci has been reported in a
study using a mouse model of S. aureus nasal colonization
[28]. The same study also showed the inability of a cap-
sule-defective mutant to persist in mouse nares, indicating
that S. aureus is encapsulated in the nares. The rate of
methicillin resistance among CoNS isolates colonizing
anterior nares of patients undergoing haemodialysis is
reported to be higher than that of S. aureus isolates; this is
accompanied by the lack of susceptibility to other classes
of antibiotics [7]. Although S. epidermidis is responsible
for most CoNS infections, other CoNS species have been
associated with a variety of human diseases [6]. For exam-
ple, S. haemolyticus is the second most commonly
encountered species in clinical infections, and S. lugdunen-
sis is a more recently described CoNS species [29].
In this context, we evaluated the bactericidal activity of
P128 on S. aureus and other staphylococcal species recov-
ered from human nares. As the first step, we characterized
the nasal commensal bacteria of 31 healthy people. Specia-
tion was carried out using the HiStaph identification kit
and the S. aureus carriage rate was also determined. Nasal
Staphylococci of 71% of the healthy people sampled con-
sisted of CoNS species, predominantly S. epidermidis and
S. aureus was found in the remaining 29% of people.
Other CoNS among nasal commensal bacteria included
S. haemolyticus and S. lugdunensis (Table 3). We exam-
ined nasal commensal populations in two randomly
selected healthy people for comparability between the two
nares with respect to bacterial load and staphylococcal
species present and found both nares to be comparable
(data not shown).
Commensal bacteria recovered from nasal swabs of 31
healthy people were plated on blood agar, enumerated,
and characterized by Gram stain, coagulase test, and
speciation
We then evaluated the activity of P128 hydrogel on
nasal Staphylococci of 31 healthy people.
In case of nasal swabs immersed in buffer-gel, colonies
were numerous, ranging from 103 - 105 CFU; estimated
based on results of a preliminary experiment, where S.
aureus cells of known CFU counts (103, 104 and 105
CFU) were plated to vizualize the pattern of growth after
overnight incubation of plates (data not shown). Of the
swabs immersed in P128 hydrogel, 4/31 showed > 99.99%
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reduction in staphylococcal cell counts, 17/31 showed
99.9% reduction, 5/31 showed 99% reduction, and 5/31
showed 90% reduction (Table 4). A few colonies that
grew on the plate containing P128 were found to be sen-
sitive to the protein when tested, and hence apparently
escaped the protein action.
This finding shows that P128 is bactericidal to nasal sta-
phylococcal isolates. However, we did not evaluate the
presence of capsular polysaccharides, which may be
assessed in future studies in our laboratory. It is important
to note that the cells were treated with P128 hydrogel
immediately after isolation (i.e., without exposure to any
other medium or subjection to any steps of cultivation).
We conclude that both S. aureus and CoNS are suscepti-
ble to P128 in the physiological state relevant to nasal car-
riage. Considering the pathogenic potential and multidrug
resistance of these species, it is significant that these spe-
cies were fully sensitive to P128. Further studies are
needed to determine the MIC and MBC of P128 on CoNS.
Reports point to the endogenous origin of most infec-
tive S. aureus isolates and MRSA carriage poses an
increased risk for invasive infections compared with
MSSA carriage [30,31]. The worldwide spread of MRSA
strains, which are often multidrug-resistant [32], com-
bined with limited therapeutic options necessitates new
approaches to combat this pathogen. Recent findings
emphasize that commensal CoNS strains are also poten-
tial threats [33]. Therefore an antibacterial agent, exem-
plified by P128, which can target antibiotic resistant
S. aureus as well as other clinically significant Staphylo-
cocci would meet the current medical need and warrants
further development.
Figure 2 Kill-kinetics of P128 on S. aureus strains. Time-kill curves of P128 at three different concentrations (MIC, MIC × 4, and MIC × 16) on
five MRSA and one MSSA strains are shown. Cell control was maintained simultaneously for each strain.
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Conclusions
This report describes the development and in vitro bio-
logical characterization of a chimeric antistaphylococcal
protein designated P128, which exhibits rapid and selec-
tive antibacterial activity at low MIC values against a
broad range of staphylococcal species, including numer-
ous clinically relevant S. aureus strains.
The MIC and MBC of P128 on a global panel of clini-
cal isolates ranged from 0.5 to 64 μg/mL. P128 showed in
vitro microbicidal activity against a wide variety of sta-
phylococcal species, including many clinically relevant
S. aureus strains. With an MBC50 of 16 μg/mL, the pro-
tein was bactericidal against every S. aureus strain tested.
P128 time-kill kinetics were determined at MIC and
higher concentrations on select isolates, and P128 was
found to rapidly reduce cell numbers by 99.99%. To
develop P128 as a treatment to eliminate human nasal
carriage, P128 was formulated as a hydrogel and tested
on nasal Staphylococci recovered from healthy people.
The protein was able to kill S. aureus under conditions
representing physiological conditions. Taken together,
our findings demonstrate that P128 exhibits excellent
antistaphylococcal properties and warrants development
for therapeutic use.
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